When should Östradiol be retested?

The optimal timing for retesting estradiol depends entirely on the clinical context. In routine menopause management or hormone replacement therapy (e.g., transdermal estradiol), retesting is typically performed after 3–6 months to assess dose adequacy and safety. For fertility monitoring or menstrual cycle assessment, measurements are timed to specific cycle days (e.g., day 3–5 for baseline, or peri-ovulatory). In men with suspected estrogen excess (e.g., from aromatase activity), retesting after 4–6 weeks of intervention may be considered. Importantly, single estradiol values are of limited use because the hormone is secreted in a pulsatile manner and varies diurnally. Direct-to-consumer tests (e.g., saliva) often show high variability and are not validated for clinical decision-making. Without a clear medical indication and predefined interval, retesting is unlikely to be actionable. The evidence is based on clinical practice guidelines rather than high-quality trials. Caveat: self-interpretation without professional guidance can lead to unnecessary worry or inappropriate treatment changes.